menu
    • menu
    [{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dasatinib","moa":"ABL1 gene","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Dasatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xspray Pharma \/ Xspray Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Xspray Pharma"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dasatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nilotinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dasatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Xspray Pharma

    Menu

    Xspray Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

    Details : Xspray Pharma's lead product XS004 (dasatinib) is being evaluated in the late-stage clinical trial studies for treating patients suffering from chronic myeloid leukemia.

    Product Name : XS004

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 19, 2024

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nilotinib

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna

    Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.

    Product Name : XS003

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    July 09, 2024

    Lead Product(s) : Nilotinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024

    Details : Dasynoc (dasatinib) is an amorphous solid dispersion form & innovative protein kinase inhibitor, small molecule drug. It is being developed for the treatment of chronic myeloid leukemia.

    Product Name : Dasynoc

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    February 12, 2024

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Recipient : Eversana

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (X...

    Details : Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).

    Product Name : Dasynoc

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    February 24, 2023

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Recipient : Eversana

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed

    Xspray Pharma

    Sweden arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Study Phase : Undisclosed

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Xspray Pharma Reports Positive Results From a Study with Dasatinib During Omeprazole Treatment

    Details : Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric p...

    Product Name : HyNap-Dasa

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 30, 2020

    Lead Product(s) : Dasatinib

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth